Compass Therapeutics

Takeda Pharmaceutical (NYSE: TAK) Stock Quote Follow

Last Trade: US$16.45 0.09 0.55
Volume: 305,982
5-Day Change: 0.37%
YTD Change: 5.45%
Market Cap: US$51.160B

Latest News From Takeda Pharmaceutical

March 18, 2023
Takeda Pharmaceutical Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
OSAKA, Japan & CAMBRIDGE, Mass. / Mar 18, 2023 / Business Wire / Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279... Read More
February 18, 2023
Takeda Pharmaceutical Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
OSAKA, Japan & CAMBRIDGE, Mass. / Feb 18, 2023 / Business Wire / Takeda ( TSE:4502/NYSE:TAK ) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile... Read More
February 8, 2023
Takeda Pharmaceutical Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
OSAKA, Japan & CAMBRIDGE, Mass. / Feb 08, 2023 / Business Wire / Takeda ( TSE:4502/NYSE:TAK ) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions.... Read More
February 3, 2023
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
OSAKA, Japan & CAMBRIDGE, Mass. / Feb 03, 2023 / Business Wire / Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO ® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age. 1 Prior to today’s approval, the only... Read More
February 2, 2023
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase Inhibitor Continued Momentum With Q3 Year-to-Date Reported Revenue Growth of +13.9% and Core Revenue Growth of +4.5% at Constant Exchange Rate; Reported EPS Growth of +19.6% Approval for Dengue Vaccine, QDENGA ® in EU; U.S. FDA Priority... Read More
January 23, 2023
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023, Fruquintinib Offers a Potential New Treatment Option for Patients with Refractory Metastatic Colorectal Cancer Licensing Agreement for Fruquintinib Strengthens Takeda’s Growing Oncology Portfolio OSAKA, Japan & CAMBRIDGE, Mass. / Jan 23, 2023 / Business Wire / Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an... Read More
January 17, 2023
Takeda Recognized as a Top Employer in Canada in 2023
TORONTO , Jan. 17, 2023 /CNW/ - The Top Employers Institute has named Takeda Canada Inc. ("Takeda") a top employer in Canada for 2023. The distinction is recognized by the Top Employers Institute that certifies organizations who are focused on putting their people first through their exceptional HR policies. The Top Employers Institute program certifies organizations based on the participation and results of their HR Best... Read More
January 16, 2023
Takeda Named Global Top Employer for Sixth Consecutive Year
Achieved Global Recognition and Top Employer Certification in 22 Countries from Top Employers Institute Global Recognition Reinforces Commitment to People and Outstanding People Policies Takeda ( TSE:4502/NYSE:TAK ) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® certification for 2023. In addition to the global certification, Takeda is also recognized as... Read More
January 11, 2023
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study Approval Based on Data from the Phase 1/2 Clinical Trial Demonstrating EXKIVITY’s Clinical Benefit and Durable Responses in EGFR Exon20 Insertion+ NSCLC Results Demonstrated a Confirmed Overall Response Rate (ORR) of 28% and Median Duration of Response (DoR) of 15.8 Months per Independent Review Committee (IRC)... Read More
January 9, 2023
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Fibrosis regression observed in 50% of patients receiving fazirsiran Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine Arrowhead to host webcast... Read More
January 5, 2023
Takeda Pharmaceutical Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Results are From First and Only Phase 3 Trial in cTTP, an Ultra-Rare Disease with Limited Treatment Options cTTP is Caused by a Deficiency in ADAMTS13 Protease; 1 TAK-755 Is Designed to Replace Missing or Deficient ADAMTS13 Enzyme 2 Takeda Plans to Seek Marketing Authorization for TAK-755 as the First ADAMTS13 Replacement Therapy for the Treatment of cTTP Takeda (TSE:4502/NYSE:TAK) today announced that the totality of... Read More
December 21, 2022
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , "Astellas"), Eisai Co., Ltd. (TSE: 4523, CEO: Haruo Naito , "Eisai"), Daiichi Sankyo Company, Limited (TSE: 4568, President : Sunao Manabe , "Daiichi Sankyo") and Takeda Pharmaceutical Company Limited . (TSE: 4502 / NYSE:TAK, President and CEO Christophe Weber , "Takeda") today announced that the four... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB